H1N1 (swine flu) & the R&D-based Pharmaceutical Industry
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
The R&D-based Pharmaceutical Industry’s response to the H1N1 influenza pandemic.
On 29 September 2026 in Washington, D.C., IFPMA delivered a statement on the strategy for strengthening health emergency and risk management for health security 2026-2031 at the 63rd Directing Council of the Pan American Health Organization and ahead of the 78th WHO Regional Committee for the Americas. IFPMA welcomes the Strategy for Health Emergency Risk...
Read moreOn 25 September 2026, at the conclusion of the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response, IFPMA issued a statement, urging governments to accelerate practical commitments that strengthen preparedness for future health crises.
Read moreOn 25 September 2026 in New York City, IFPMA submitted a statement at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response. Panel 1: Multilateral action for coordinated pandemic prevention, preparedness, and response, including sharing of best practices and lessons learned so far The COVID-19 pandemic and outbreaks including Ebola have reinforced a simple...
Read more